Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 5/20 | 0.34 |
| ▸ | CA1 | P00915 | 5/20 | 0.34 |
| ▸ | CA9 | Q16790 | 5/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13640332 | 0.81 | CA12 (0.59) | DRD2CA12CA1CA9CA2 | |
| SCHEMBL4816617 | 0.81 | DRD2 (0.45) | DRD2KDM4EPOLBSMN1; SMN2NPC1 | |
| SCHEMBL3116398 | 0.79 | DRD2 (0.47) | DRD2CA12CA1CA9CA2 | |
| SCHEMBL2076161 | 0.79 | KDM4E (0.49) | DRD2KMT2AKDM4ECYP3A4MAPT | |
| SCHEMBL17337274 | 0.79 | DRD2 (0.44) | DRD2KDM4ESMN1; SMN2 | |
| SCHEMBL6049222 | 0.79 | MAOB (0.48) | DRD2KMT2AKDM4ECYP3A4MAPT | |
| SCHEMBL11862478 | 0.77 | CA2 (0.54) | CA12CA1CA9CA2ACHE | |
| SCHEMBL24167590 | 0.76 | CA1 (0.54) | DRD2CA12CA1CA9CA2 | |
| SCHEMBL16564308 | 0.76 | DRD2 (0.44) | DRD2CA12CA1CA9CA2 | |
| SCHEMBL23042779 | 0.76 | DRD2 (0.42) | DRD2CA12CA1CA9CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946289-B2 | Manassatin compounds and methods of making and using the same | DUKE UNIVERSITY (US) | 2015-02-03 | — | — | US | disclosed |
| US-20110230540-A1 | MANASSATIN COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | DUKE UNIVERSITY (US) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230540-A1 | MANASSATIN COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | HIF1AN, HIF1A, EGLN2 | DRD2 4189/4885CA12 2597/4885CA1 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.